GLP-1 receptor agonists × cardiac & vascular function

TrialLancet (London, England)2024

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.

Javed Butler et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 529 people · 2024

Randomised comparison

Probably raised cardiac & vascular function

+7.50points+5.30 to +9.80

As reported

difference 7.5 points, 95% CI 5.30–9.80

One number in the abstract

the abstract, start to end

from baseline to week 52 in KCCQ-CSS 7.5 points [95% CI 5.3 to 9.8];

← favours treatmentfavours comparator →
could be chance
Cardiac & vascular function
7.55.30–9.80
GLP-1 receptor agonistsCardiac & vascular function

GLP-1 receptor agonists × cardiac & vascular functionhelps?mixed

unlikelylikely
0.500.50 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

153 papers cite itlatest 60 shown

2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 38599221